PharmaGap Files Provisional Patent Application for Liposomal Formulations of GAP-107B8
October 03 2011 - 7:38AM
Marketwired
PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the
Company") is pleased to announce that it has filed the second of
two provisional patent applications with the United States Patent
and Trademark Office ("USPTO") covering the results of development
of PharmaGap's lead cancer drug GAP-107B8 during 2011 to date.
These two provisional patent filings covering the GAP-107B8
formulations represent significant steps forward in the Company's
ability to realize value from the Company's drug development
program.
This filing, titled "Liposomal Formulations of Cationic Peptides
and Uses Thereof" addresses the liposome formulations developed by
PharmaGap as well as these liposomal formulations carrying the
original or modified versions of GAP-107B8. Liposomes consist of
one or more concentric lipid layers enclosing an internal aqueous
volume and are unique in their ability to carry a variety of
therapeutic compounds. The specific lipids used in constructing the
liposome can be selected to facilitate interaction with the drug
cargo and/or with the target cell, making these systems extremely
versatile drug delivery systems.
The successful development of these liposomal formulations of
original and modified GAP-107B8 has significantly widened the
GAP-107B8 Therapeutic Window (the range of doses between the lowest
effective dose and the highest dose where unacceptable toxicity
becomes evident), a key consideration for effective clinical trial
design and ultimate success of the drug in the marketplace.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is
a novel peptide drug that has been shown to be highly cytotoxic to
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management's current expectations of future events, and
can be identified by words such as "believe", "expects", "will",
"intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes
that expectations represented in such forward-looking statements
are reasonable, there can be no assurance that they will prove to
be correct.
By their nature, forward-looking statements include assumptions
and are subject to inherent risks and uncertainties that could
cause actual future results, conditions, actions or events to
differ materially from those in the forward-looking statements. If
and when forward-looking statements are set out in this news
release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except
as expressly required by applicable securities laws, the Company
assumes no obligation to update or revise any forward-looking
statements. The future outcomes that relate to forward-looking
statements may be influenced by many factors, including, but not
limited to: results of ongoing product testing and development;
regulatory approvals required to complete development of products;
ability to manufacture product at quality and scale for human use
on an economically sound basis; patient reimbursement by private
and public health insurance programs; unintended side effects of
products; competitive products; product liability; intellectual
property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of
financing; distribution of securities; effect of market interest
rates on price of securities, and potential dilution.
Note: Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This
release contains forward looking statements that may not occur or
may change materially.
Contacts: PharmaGap Inc. Robert McInnis President & CEO
613-990-9551bmcinnis@pharmagap.com
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Oct 2023 to Oct 2024